Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Clark Estates Inc. NY

Clark Estates Inc. NY reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 17.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,100 shares of the medical equipment provider's stock after selling 8,200 shares during the period. Lantheus makes up approximately 0.8% of Clark Estates Inc. NY's portfolio, making the stock its 18th biggest position. Clark Estates Inc. NY owned about 0.06% of Lantheus worth $4,291,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of LNTH. Moloney Securities Asset Management LLC acquired a new position in Lantheus in the 3rd quarter valued at about $1,066,000. Hancock Whitney Corp grew its holdings in shares of Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock valued at $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in Lantheus during the 2nd quarter worth approximately $290,000. Van ECK Associates Corp increased its stake in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock worth $6,469,000 after buying an additional 21,604 shares during the period. Finally, Swedbank AB lifted its holdings in Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock worth $79,266,000 after buying an additional 125,843 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. JMP Securities lowered their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research note on Thursday, November 7th. Truist Financial reaffirmed a "buy" rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Price Performance

Shares of LNTH traded up $0.93 during mid-day trading on Wednesday, reaching $90.46. 959,853 shares of the company's stock were exchanged, compared to its average volume of 1,022,815. The business's fifty day simple moving average is $102.48 and its 200-day simple moving average is $97.13. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market capitalization of $6.29 billion, a PE ratio of 14.90 and a beta of 0.51.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.